Agilent Technologies has developed a patent for modified prime editing guide RNAs (pegRNAs) that enable precise editing of target DNA or RNA using CRISPR/Cas technology. The pegRNAs contain chemically-modified nucleotides, allowing for targeted mutagenesis or nucleotide changes. GlobalData’s report on Agilent Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agilent Technologies, Microfluidics automation was a key innovation area identified from patents. Agilent Technologies's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Modified prime editing guide rna for crispr/cas-based editing
A recently granted patent (Publication Number: US11884915B2) discloses a prime-editing guide RNA (pegRNA) designed for precise editing of target sequences in nucleic acids. The pegRNA comprises a guide sequence that hybridizes to the target region, a segment interacting with a Cas protein, a primer-binding site, and a reverse transcriptase template segment with desired edits. Notably, the pegRNA contains modified nucleotides, specifically 2'-O-methyl-3'-phosphonoacetate ("MP"), within 5 nucleotides of the prime-editing end. Various embodiments of the pegRNA include different configurations of modified nucleotides, extension tails, and additional modifications to enhance editing efficiency.
The patent also covers methods for editing target regions using the pegRNA in conjunction with a nickase Cas protein and a reverse transcriptase. The process involves contacting the target region with the components, resulting in precise editing of the nucleic acid. Additionally, the patent describes variations in the delivery of Cas protein and reverse transcriptase, including covalent linkage in fusion proteins, mRNA delivery, or encapsulation in nanoparticles. Furthermore, the methods extend to editing multiple nucleic acid target regions simultaneously by utilizing specific pegRNAs for each region, showcasing the versatility and potential applications of this prime-editing technology in genetic engineering and therapeutic interventions.
To know more about GlobalData’s detailed insights on Agilent Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
